| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
9-[5-Deoxy-5-[[cis-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methylethyl)amino]-β-D-ribofuranosyl]-9H-purin-6-amine | 1380288-87-8 | sc-500607 | 50 mg | $13500.00 | ||
This small molecule inhibitor targets the DOT1L enzyme, which is involved in the regulation of AF-It has been investigated for its potential in MLL-rearranged leukemia. | ||||||
Epz004777 | 1338466-77-5 | sc-507560 | 100 mg | $575.00 | ||
This compound targets the AF10-BRD9 interaction and has been investigated for its anti-leukemic effects. | ||||||
GSK J1 | 1373422-53-7 | sc-391113 sc-391113A | 10 mg 50 mg | $193.00 $813.00 | ||
Although primarily known as a histone demethylase inhibitor, GSK-J1 has been studied for its impact on MLL-AF10 leukemia. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
This compound is a potent inhibitor of the menin-MLL interaction, which is relevant in MLL-fusion leukemias. | ||||||